Portage Biotech: Pausing Further Drug Development in the PORT-2 INKT Program >PRTG
Portage Biotech: Pausing Further Drug Development in the PORT-2 INKT Program >PRTG
Portage Biotech：暂停 PORT-2 INKT 计划的进一步药物开发 >PRTG
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册